ELV has staged a sharp recovery this week, but the real story is what's happening on the Street — a wave of analyst target upgrades that has effectively validated the rebound and is still running ahead of where the stock now trades.
The analyst activity has been unusually coordinated. In the past two weeks alone, every major firm covering ELV raised its price target. JP Morgan lifted its target from $411 to $476 on June 8, maintaining Overweight. The day before, Mizuho moved to $465 from $435. Bank of America was already there on June 4, taking its target to $460 from $435 on a Buy rating. Deutsche Bank's upgrade on May 20 — shifting from Hold to Buy with a target jump to $498 from $363 — may have been the catalyst that got the rally rolling. The direction of travel is unmistakable: eleven target raises in roughly three weeks, zero cuts. The consensus mean target now sits near $416, modestly below the current $424.43 close, which means the stock has caught up to — and in some cases already passed — several of the older targets in the group. The active upgrades from JPM, Mizuho, and Deutsche Bank all point to $465–$498, suggesting the Street believes there is still room to run.
What's driving the bullish pivot is a reassessment of the margin outlook. The bull case centers on Medicare Advantage margins expanding more than 150 basis points in 2026, with favorable pricing and an improving membership mix in dual-eligible plans. The bears counter that Medicaid remains a drag — guidance implied a breakeven margin there — and that commercial pressures and rising medical costs could weigh on the second half. EV/EBITDA has moved up nearly a full turn over the past month to around 11.4x, and the P/E has expanded by roughly 1.4 points over the same stretch to 15.2x, reflecting the market's growing willingness to re-rate the stock. The analyst recommendation divergence factor scores in the 92nd percentile across the universe — a signal that the Street is unusually bullish relative to history, even with the hold consensus from the lower-rated names.
The positioning picture is notably uncrowded for a stock that has rallied 9% in a week. Short interest has risen in absolute terms — up roughly 16% week-on-week to 3.1% of the float — and borrowing costs have ticked higher, up nearly 40% over the same stretch to 0.55%. Both moves are real, but context matters: availability remains extraordinarily loose at over 5,400%, meaning there are vastly more shares available to borrow than are currently shorted. The lending market is nowhere near stressed. Options positioning reinforces this: the put/call ratio is running at 0.66, essentially in line with its 20-day average and near the lower end of its 52-week range of 0.60–0.91. There is no sign of defensive hedging being layered on as the stock recovers.
The peer group recovered broadly this week, with HUM up 13%, MOH up 13%, and UNH up 9% — ELV's 9% gain puts it in the middle of the pack rather than leading the sector's rehabilitation. The institutional roster is stable, with BlackRock holding 9.2% and the passive complex broadly unchanged. Insider activity is worth a brief note: the 90-day net figure is a modest positive ($7M net), though the underlying trades are mostly small executive sales from March. The one genuine open-market buy — Director Steven Collis picking up 3,000 shares at $289.84 in March — looks well-timed in hindsight.
Q2 results are due July 15. The key watch point is whether Medicaid margin trends for the back half match or improve on Q1 data, given that the Street has collectively lifted its view on the assumption that the worst of the redetermination headwinds have passed.
See the live data behind this article on ORTEX.
Open ELV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
